When these interventions were combined, tumor weight and volume were significantly reduced, supporting the hypothesis that simultaneous disruption of the CXCL12/CXCR4 axis and IL-2 modulation could reshape immune functionality within the TME. This evidence concerns the gene CXCL12 and neoplasm.